Loading
Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.
Mavrostobart (PT199) is a monoclonal antibody developed by Phanes Therapeutics. Its target is CD73 / adenosine axis. ClinicalTrials.gov describes the intervention as: Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT05431270, plans to enrol 40 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Monoclonal antibody directed at CD73 / adenosine axis, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to CD73 / adenosine axis.
1.Mavrostobart binds CD73 / adenosine axis.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mavrostobart" OR ABSTRACT:"Mavrostobart" OR TITLE:"PT199" OR ABSTRACT:"PT199" OR TITLE:"Mavrostobart PT199" OR ABSTRACT:"Mavrostobart PT199") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mavrostobart, not a curated reading list.
Shares Phanes Therapeutics, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Phanes Therapeutics, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.